Skip to main content

Advertisement

SpringerLink
Log in

What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?

  • Lymphoma (JW Sweetenham, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

The front-line management of patients with chronic lymphocytic leukemia (CLL) has evolved significantly in recent years due to introduction of novel, targeted agents. Upon CLL diagnosis, physicians should determine whether treatment or careful observation is indicated. Once treatment is required, choice of therapy should be based on the age and fitness of the patient and the distinct molecular profile of their disease. As multiple novel agents are in various stages of development, all patients regardless of their age, fitness, and disease risk should be evaluated for clinical trial participation before initiating any front-line therapy. If no clinical trial is available, we provide our recommendations for front-line treatment of CLL patients. Healthy, young patients with low-risk disease (mutated IgVH, del (13q)) should be offered fludarabine, chlorambucil, and rituximab (FCR), while similar patients with high-risk disease (unmutated IgVH, del (17p), del (11q), and complex karyotype) should be considered for ibrutinib therapy. For those young, fit patients with high-risk disease and a contraindication to ibrutinib, FCR, or high-dose methylprednisolone and rituximab are options. In regard to older, unfit patients, a careful assessment of their fitness and ability to tolerate treatment should be undertaken before starting therapy. Those who have poor performance and multiple medical comorbidities should be considered for palliative care alone. However, those who are fit enough for treatment can be offered ibrutinib. If there is a contraindication to ibrutinib, they can be separated into low- and high-risk molecular groups. For the low-risk patients, bendamustine and rituximab or obinutuzumab and chlorambucil can be considered. For the high-risk patients, treatment with rituximab and lenalidomide is an option. Herein, we provide an evidence-based front-line treatment algorithm for CLL patients based upon fitness and molecular risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Hallek M, Pflug N. Chronic lymphocytic leukemia. Ann Oncol. 2010;21(Suppl 7):154–64. doi:10.1093/annonc/mdq373.

    Google Scholar 

  2. Pflug N, Bahlo J, Shanafelt TD, Eichhorst BFBMA, Elter T, Bauer K, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014;124(1):49–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848–54.

    CAS  PubMed  Google Scholar 

  4. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–6. doi:10.1056/nejm200012283432602.

    Article  CAS  PubMed  Google Scholar 

  5. Mayr C, Speicher MR, Kofler DM, Buhmann R, Strehl J, Busch R, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood. 2006;107(2):742–51. doi:10.1182/blood-2005-05-2093.

    Article  CAS  PubMed  Google Scholar 

  6. Linn BS, Linn MW, Gurel L. Cumulative Illness Rating Scale. J Am Geriatr Soc. 1968;16(5):622–6.

    Article  CAS  PubMed  Google Scholar 

  7. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet (London, England). 2010;376(9747):1164–74. doi:10.1016/s0140-6736(10)61381-5.

    Article  CAS  Google Scholar 

  8. Thompson PA, Tam CS, O’Brien SM, Wierda WG, Stingo F, Plunkett W, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127(3):303–9. doi:10.1182/blood-2015-09-667675.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Strati P, Keating MJ, O’Brien SM, Burger J, Ferrajoli A, Jain N, et al. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014;123(24):3727–32. doi:10.1182/blood-2013-11-538116.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. • Eichhorst B, Fink AM, Busch R, Kovacs G, Maurer C, Lange E, et al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international, randomized study of the German CLL study group (GCLLSG) (CLL10 study). Blood. 2014;124(21):19. Phase 3 study demonstrates that FCR is likely more efficacious than BR in front-line therapy of young CLL patients.

    Google Scholar 

  11. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42. doi:10.1056/NEJMoa1215637.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123(12):1810–7. doi:10.1182/blood-2013-09-527853.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–23. doi:10.1056/NEJMoa1400376.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Farooqui MZ, Valdez J, Martyr S, Aue G, Saba N, Niemann CU, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. The Lancet Oncology. 2015;16(2):169–76. doi:10.1016/s1470-2045(14)71182-9.

    Article  CAS  PubMed  Google Scholar 

  15. •• Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–37. doi:10.1056/NEJMoa1509388. Phase 3 study of ibrutinib vs chlorambucil in front-line CLL demonstrating superiority of ibrutinib

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Castro JE, James DF, Sandoval-Sus JD, Jain S, Bole J, Rassenti L, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia. 2009;23(10):1779–89. doi:10.1038/leu.2009.133.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Golay J, Da Roit F, Bologna L, Ferrara C, Leusen JH, Rambaldi A, et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood. 2013;122(20):3482–91. doi:10.1182/blood-2013-05-504043.

    Article  CAS  PubMed  Google Scholar 

  18. • Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–10. doi:10.1056/NEJMoa1313984. Phase 3 study in older unfit CLL patients demonstrating superiority of obinutuzumab + chlorambucil over chlorambucil alone

    Article  CAS  PubMed  Google Scholar 

  19. James DF, Werner L, Brown JR, Wierda WG, Barrientos JC, Castro JE, et al. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(19):2067–73. doi:10.1200/jco.2013.51.5890.

    Article  CAS  Google Scholar 

  20. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–8. doi:10.1038/nm.3048.

    Article  CAS  PubMed  Google Scholar 

  21. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–22. doi:10.1056/NEJMoa1513257.

    Article  CAS  PubMed  Google Scholar 

  22. Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. The Lancet Oncology. 2016;17(6):768–78. doi:10.1016/s1470-2045(16)30019-5.

    Article  CAS  PubMed  Google Scholar 

  23. Byrd JC, Harrington B, O’Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323–32. doi:10.1056/NEJMoa1509981.

    Article  CAS  PubMed  Google Scholar 

  24. Byrd JCJ, Furman, R.R., Stephens, D.M., Devereux, S., Brown, J.R., Hillmen, P., Hamdy, A.M., Fardis, M., Tawashi, M., Wang, M.H., Patel, P., Mittag, D., Krantz, F., Rothbaum, W., Izumi, R., O'Brien, S.M., Wierda, W.G., 2016, (eds) Acalabrutinib, a second-generation bruton tyrosine kinase (Btk) inhibitor, in previously untreated chronic lymphocytic leukemia (CLL). American Association of Clinical Oncology; Chicago, Illinois: Journal of Clinical Oncology.

  25. Walter HS, Rule SA, Dyer MJ, Karlin L, Jones C, Cazin B, et al. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016;127(4):411–9. doi:10.1182/blood-2015-08-664086.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007. doi:10.1056/NEJMoa1315226.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016;128(2):195–203. doi:10.1182/blood-2016-03-707133.

    Article  CAS  PubMed  Google Scholar 

  28. O'Connor OA, Flinn IW, Patel MR, Fenske TS, Deng C, Brander DM, et al. TGR-1202, a novel once daily PI3K-Delta inhibitor, demonstrates clinical activity with a favorable safety profile in patients with CLL and B-cell lymphoma. Blood. 2015;126(23):4154.

    Google Scholar 

Download references

Acknowledgements

The authors would like to thank Denise Scafuto-Pessetto with assistance in preparation of the figure.

Author information

Authors and Affiliations

  1. Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah, Salt Lake City, UT, 84112, USA

    Benjamin N. Voorhies M.D. & Deborah M. Stephens D.O

  2. Huntsman Cancer Institute, University of Utah, 1950 Circle of Hope, Room 3364, Salt Lake City, UT, 84112, USA

    Deborah M. Stephens D.O

Authors
  1. Benjamin N. Voorhies M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deborah M. Stephens D.O
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deborah M. Stephens D.O.

Ethics declarations

Conflict of Interest

The authors declare that they no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Lymphoma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Voorhies, B.N., Stephens, D.M. What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?. Curr. Treat. Options in Oncol. 18, 12 (2017). https://doi.org/10.1007/s11864-017-0450-8

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-017-0450-8

Keywords

Search

Navigation